Takahiro Takazono
Overview
Explore the profile of Takahiro Takazono including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
181
Citations
993
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iwanaga N, Hosogaya N, Takazono T, Tsukamoto Y, Morio R, Irifune S, et al.
Cureus
. 2025 Mar;
17(3):e80404.
PMID: 40078884
Background And Objective: For treating community-acquired pneumonia (CAP) in adults, early switching from injectable to oral antimicrobials (switch therapy) is accepted once the clinical course is favorable. Lascufloxacin (LSFX) is...
2.
Namie H, Takazono T, Kawasaki R, Yano H, Ito Y, Nakada N, et al.
Respir Investig
. 2025 Mar;
63(3):303-310.
PMID: 40048846
Background: Post-COVID-19 syndrome, referred to as "long COVID," is characterized by persistent symptoms that develop during or after SRAS-CoV-2 infection lasting for ≥12 weeks, which cannot be explained by factors...
3.
Takazono T, Hosogaya N, Ideguchi R, Yoshida M, Takeda K, Ide S, et al.
Cureus
. 2025 Mar;
17(3):e79891.
PMID: 40034415
Introduction complex pulmonary disease (MAC-PD) necessitates prolonged treatment. However, determining the appropriate time to conclude treatment is challenging because of the lack of indices for evaluating disease activity. Fluorodeoxyglucose positron...
4.
Tashiro M, Nakano Y, Shirahige T, Kakiuchi S, Fujita A, Tanaka T, et al.
J Fungi (Basel)
. 2025 Feb;
11(2).
PMID: 39997390
As azole-resistant emerges globally, healthcare facilities face mounting challenges in managing invasive aspergillosis. This review synthesizes worldwide azole resistance data to reveal profound regional variability, demonstrating that findings from other...
5.
Cornely O, Sprute R, Bassetti M, Chen S, Groll A, Kurzai O, et al.
Lancet Infect Dis
. 2025 Feb;
PMID: 39956121
Candida species are the predominant cause of fungal infections in patients treated in hospital, contributing substantially to morbidity and mortality. Candidaemia and other forms of invasive candidiasis primarily affect patients...
6.
Murai Y, Murai Y, Nagaoka K, Nagaoka K, Iwanaga N, Iwanaga N, et al.
Int J Infect Dis
. 2025 Feb;
153:107840.
PMID: 39929321
Objectives: Routine clinical practice with extended anaerobic antibiotic coverage (EAC) has been recently reconsidered for several infections; however, its benefits remain unclear even in patients with anaerobic bacteremia (AB). Here,...
7.
Torigoe K, Yamashita Y, Yamashita A, Ota Y, Kitamura M, Sakimura N, et al.
Cureus
. 2025 Feb;
17(1):e77248.
PMID: 39925597
An 82-year-old woman undergoing peritoneal dialysis (PD) presented to our hospital with cloudy PD effluent since four days. The leukocyte count in the effluent was elevated to 2900/μL, and the...
8.
Obase Y, Fukahori S, Iriki J, Tsukamoto Y, Nagae Y, Takemoto S, et al.
Intern Med
. 2025 Feb;
PMID: 39924246
Objective The prevalence rates of bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) are 3%-11% and 8%-16%, respectively, in the general Japanese adult population. Few reports on patients' perceptions...
9.
Okuno D, Sakamoto N, Hayashi H, Fukuda T, Akiyama Y, Iketani C, et al.
ChemMedChem
. 2025 Jan;
:e202401001.
PMID: 39887929
Idiopathic pulmonary fibrosis (IPF) is a progressive and chronic interstitial lung disease characterized by irreversible loss of lung function and a poor prognosis. Type I collagen, a major component of...
10.
Takazono T, Ide S, Adomi M, Ogata Y, Saito Y, Yoshida M, et al.
Mycoses
. 2025 Jan;
68(1):e70022.
PMID: 39777801
Objective: The global prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) has been steadily increasing. A few small retrospective studies have reported a poor prognosis associated with chronic pulmonary aspergillosis (CPA)...